List of Excipients in Branded Drug PHEBURANE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medunik USA	PHEBURANE	sodium phenylbutyrate	71770-100	ETHYLCELLULOSES
Medunik USA	PHEBURANE	sodium phenylbutyrate	71770-100	HYPROMELLOSE 2910
Medunik USA	PHEBURANE	sodium phenylbutyrate	71770-100	POLYETHYLENE GLYCOL 1500
Medunik USA	PHEBURANE	sodium phenylbutyrate	71770-100	POVIDONE K25

Pheburane Excipient Strategy and Commercial Opportunities

Last updated: August 13, 2026

Pheburane is a differentiated oral granule formulation of sodium phenylbutyrate for chronic treatment of urea cycle disorders. Its commercial value is driven less by the active ingredient, which is established and available in other products, than by taste masking, pediatric administration, dose flexibility, and adherence. The strongest excipient opportunity is a next-generation granule or multiparticulate system that improves palatability without increasing sodium exposure, dose volume, manufacturing complexity, or regulatory burden.

What is Pheburane and how does its formulation differ?

Pheburane contains sodium phenylbutyrate in oral granules. Each gram of granules contains approximately 483 mg of sodium phenylbutyrate, equivalent to the labeled strength used for dose calculation. The product is administered orally and can be mixed with food or liquid, which is important because patients with urea cycle disorders often require lifelong treatment and may include infants, children, and patients with swallowing difficulties.[1]

Pheburane differs from conventional sodium phenylbutyrate products in dosage form and administration profile:

Attribute	Pheburane	Buphenyl tablets or powder
Active ingredient	Sodium phenylbutyrate	Sodium phenylbutyrate
Dosage form	Oral granules	Tablets and powder
Primary formulation objective	Taste-masked, flexible pediatric administration	Conventional oral delivery
Dose flexibility	High, using measured granules	High with powder; lower with tablets
Administration	Mixed with food or liquid	Tablets or powder
Main commercial differentiation	Palatability and usability	Established reference-product position
Therapeutic category	Urea cycle disorder treatment	Urea cycle disorder treatment

Pheburane received U.S. Food and Drug Administration approval under NDA 214992 in December 2022. The product is marketed in the United States by Medunik USA and is associated with Medunik Canada and related commercial entities.[2]

What excipients are used in Pheburane?

The Pheburane formulation uses excipients associated with granule formation, coating, flow, and taste masking. Public product information identifies coating and processing materials including ethylcellulose, hypromellose, povidone, sodium lauryl sulfate, and related formulation excipients, depending on the applicable jurisdiction and product presentation.[3,4]

Ethylcellulose and hypromellose

Ethylcellulose is the most commercially relevant excipient in the taste-masking strategy. It can form a water-insoluble or low-permeability coating that reduces immediate contact between sodium phenylbutyrate and oral taste receptors. Hypromellose can modify film formation, coating integrity, wetting, and release behavior.

The formulation challenge is substantial. Sodium phenylbutyrate is administered at gram-level doses, and the active ingredient has a strong, unpleasant taste. A coating that is effective at low drug load may become impractical when scaled to the high daily doses used in urea cycle disorders.

Povidone

Povidone can support granulation and improve particle cohesion. Its value is primarily manufacturing-related, but it also affects granule hardness, disintegration, and coating performance.

Sodium lauryl sulfate and wetting agents

Surfactants may improve wetting and coating uniformity. Their concentration must remain low because high surfactant levels can affect taste, gastrointestinal tolerability, foaming, and dissolution.

Excipient strategy in commercial terms

The excipients have four business functions:

1. Reduce sodium phenylbutyrate taste intensity.
2. Produce granules that can be measured accurately.
3. Maintain physical stability during storage and handling.
4. Permit administration with food or liquid without unacceptable agglomeration or rapid taste release.

The excipient estate is therefore more likely to support formulation and manufacturing claims than composition-of-matter claims covering sodium phenylbutyrate.

What formulation attributes create commercial value for Pheburane?

Pheburane's commercial opportunity is concentrated in adherence. Urea cycle disorders require chronic nitrogen-scavenging therapy. Poor taste, large doses, and complex administration can lead to missed doses, especially in pediatric patients.

Taste masking

Taste masking is the principal value driver. A successful system must suppress bitterness during the short period between oral administration and swallowing. It does not necessarily need to prevent all drug release in the gastrointestinal tract.

Potential technical approaches include:

• Ethylcellulose or polymetric film coating.
• Polymer-lipid hybrid coatings.
• Ion-exchange resin complexes.
• Lipid-coated multiparticulates.
• Microencapsulation.
• Fluid-bed coated granules.
• Functional coating combined with flavor-compatible food administration.

For a high-dose product, the coating must be thin enough to avoid excessive dose mass but robust enough to survive manufacturing, packaging, transport, and administration.

Pediatric dose flexibility

Pheburane granules allow dosing across age and body-weight ranges. This is commercially important because urea cycle disorder treatment is weight-based and often changes as children grow.

A competing formulation that offers smaller dose increments, unit-dose sachets, or calibrated dosing devices could gain share even without changing the active ingredient.

Administration with food or liquid

The ability to mix granules with a permitted vehicle expands use in patients who cannot swallow tablets. This also creates an opportunity for a co-packaged administration system, such as:

• Premeasured sachets.
• Oral syringes.
• Dosing spoons with controlled granule delivery.
• Compatible neutral-flavor soft foods.
• Ready-to-use suspension systems.

Any such system would require careful control of dose recovery. Granules that adhere to cups, spoons, feeding tubes, or food containers can produce clinically relevant dose loss.

When does Pheburane lose exclusivity?

Pheburane's principal U.S. regulatory protection is expected to be orphan-drug exclusivity rather than a broad new-chemical-entity exclusivity period. The active moiety, sodium phenylbutyrate, was previously approved in the United States through Buphenyl.

FDA approved Pheburane in December 2022 for chronic management of patients with urea cycle disorders who cannot be adequately managed by dietary protein restriction and supplementation alone.[1,2] If the product received orphan-drug exclusivity for the approved indication, the seven-year period would generally run through December 2029, subject to the scope of the designation and FDA's statutory exceptions.

Milestone	Date or status
Sodium phenylbutyrate precedent product	Buphenyl approved before Pheburane
Pheburane U.S. approval	December 2022
Likely orphan exclusivity endpoint	December 2029
Active-ingredient exclusivity	Not a new active moiety
Formulation patent expiry	Must be assessed from issued claims and terminal disclaimers
Generic entry before orphan expiry	Potentially constrained for the same orphan indication, but not necessarily eliminated for all products or indications

Orphan exclusivity is not equivalent to patent exclusivity. It generally restricts FDA approval of the same drug for the same orphan indication, but it does not automatically block every formulation, every indication, or every litigation pathway.

What patents protect Pheburane?

The highest-value patent claims would likely cover the following subject matter:

• Taste-masked sodium phenylbutyrate granules.
• Coated particles containing sodium phenylbutyrate.
• Specific polymer combinations.
• Coating weight gain and particle-size distributions.
• Granules suitable for administration with food or liquid.
• Methods of reducing bitterness.
• Manufacturing processes using fluid-bed coating or related equipment.
• Dose forms that maintain stability under defined humidity conditions.

A patent analysis should distinguish four categories:

Patent category	Commercial relevance	Typical vulnerability
Active ingredient	Low for Pheburane differentiation	Prior-art and expiration barriers
Formulation composition	High	Design-around using different polymers or structures
Manufacturing process	Medium to high	Difficult to detect infringement without discovery
Method of use	Medium	Indication and label limitations can narrow enforcement

Public FDA approval materials and product labeling do not establish the full patent position. Patent protection must be evaluated through issued claims, continuations, national-phase filings, terminal disclaimers, and assignment records. A formulation patent with narrow coating parameters may protect Pheburane commercially while leaving open multiple alternative granule designs.

Does Pheburane have Orange Book-listed patents?

Pheburane's Orange Book position should be evaluated separately from its orphan exclusivity. Orange Book listings, if present, would normally identify patents that the NDA holder asserts cover the approved drug, its formulation, or an approved method of use.[5]

The commercial questions are:

• Whether Pheburane has listed formulation patents.
• Whether any listed patents expire before or after December 2029.
• Whether the listed claims cover the granule product specifically.
• Whether a generic applicant could submit a Paragraph IV certification.
• Whether the applicant could use a Paragraph III certification with a delayed launch.
• Whether the proposed generic can carve out protected methods of use.

For a sodium phenylbutyrate product, the most plausible Paragraph IV target would be a formulation patent rather than a compound patent. A generic applicant could attempt to use a different coating polymer, a different particle architecture, or an uncoated powder product that relies on a different administration method.

Which companies are challenging Pheburane?

No broad competitive challenge should be assumed solely because sodium phenylbutyrate is an established active ingredient. The relevant competitors fall into three groups:

Existing sodium phenylbutyrate products

Buphenyl remains the key reference product category. It has established regulatory history but presents administration and palatability limitations relative to a taste-masked granule.

Generic manufacturers

Generic manufacturers may target sodium phenylbutyrate tablets or powder rather than Pheburane's exact granule technology. A generic granule product would face formulation development challenges, including taste masking, dose uniformity, stability, and non-infringement.

Alternative nitrogen scavengers

Ravicti, an oral liquid containing glycerol phenylbutyrate, competes in the same disease category. It has a different active ingredient and delivery system. Ravicti reduces the need for repeated large-volume sodium phenylbutyrate administration but carries its own cost, dosing, and regulatory considerations.[6]

How does Pheburane compare with Ravicti and Buphenyl?

Product	Active ingredient	Form	Formulation advantage	Key limitation
Pheburane	Sodium phenylbutyrate	Taste-masked granules	Pediatric flexibility and improved palatability	Sodium load and large gram-level dosing
Buphenyl	Sodium phenylbutyrate	Tablets or powder	Established product and clinical familiarity	Strong taste, tablet burden, administration complexity
Ravicti	Glycerol phenylbutyrate	Oral liquid	Lower dosing volume and different administration profile	High cost, liquid handling, separate active ingredient

Pheburane's strategic position is between conventional sodium phenylbutyrate and higher-cost liquid nitrogen scavenger therapy. Its best commercial segment is likely patients who need the sodium phenylbutyrate mechanism but cannot tolerate the taste or administration burden of tablets and powder.

What excipient-driven commercial opportunities exist?

Next-generation taste masking

A competing product could use a coating system with lower polymer loading, stronger mechanical resistance, or improved release control. The objective would be to reduce the total administered mass and improve mouthfeel.

A successful formulation should be evaluated against:

• Immediate bitterness.
• Residual aftertaste.
• Granule fracture during handling.
• Dissolution after administration with food.
• Compatibility with enteral feeding.
• Stability under high humidity.
• Dose recovery from administration vessels.

Sodium-reduced or sodium-free alternatives

Sodium exposure is a structural limitation of sodium phenylbutyrate. Patients with liver disease, renal impairment, hypertension, or fluid-management concerns may be sensitive to sodium burden.

A sodium-free phenylbutyrate prodrug or alternative salt could create a larger commercial opportunity, but it would be a new active-ingredient or new active-moiety development program rather than a simple excipient improvement. It would carry higher clinical, CMC, and regulatory costs.

Pediatric unit-dose packaging

Unit-dose sachets could reduce dosing errors and improve adherence. The strongest product design would combine:

• Weight-band dosing.
• Clear sachet strengths.
• Tamper-evident packaging.
• Moisture protection.
• Low-residue transfer.
• A measuring device for intermediate doses.

Packaging IP may complement formulation IP, although it is generally easier to design around than a well-supported formulation claim.

Flavor-compatible administration vehicles

Pheburane is administered with food or liquid. A licensed or co-marketed neutral-flavor vehicle could improve consistency and reduce caregiver uncertainty. The vehicle would need to preserve granule integrity and avoid premature coating failure.

Specialty-pharmacy support

The disease population is small, and the treatment is chronic. Commercial programs can focus on prescription persistence, dosing education, shipment coordination, and caregiver support. These services are not excipients, but they can amplify the value of a formulation that reduces administration friction.

What manufacturing and IP barriers affect market entry?

The main manufacturing barrier is reproducible coating at high active load. Critical process parameters include:

• Granule size distribution.
• Coating thickness.
• Spray rate.
• Inlet and product temperature.
• Residual solvent or moisture.
• Attrition during fluid-bed processing.
• Content uniformity.
• Dissolution after storage.

A generic developer must show that its product performs consistently even if it does not use the same excipient system. A non-infringing design could use a different polymer, a different coating sequence, or a different particle core. The design must still meet bioavailability, stability, palatability, and dose-uniformity requirements.

Regulatory risk is higher if the product's clinical performance depends on administration with specific foods or liquids. Those conditions may require clear labeling, compatibility studies, and potentially additional bridging work.

What is the revenue exposure and market opportunity?

The relevant market is an orphan specialty market with high treatment persistence but limited patient volume. Revenue depends on:

• Urea cycle disorder prevalence and diagnosis.
• Pediatric treatment initiation.
• Payer coverage.
• Switching from Buphenyl.
• Competition from Ravicti.
• Generic timing.
• Net price after discounts.
• Continuation into adulthood.

Pheburane can justify premium pricing if it demonstrates better adherence, lower caregiver burden, fewer administration failures, or improved persistence. The product is less defensible if payers view it as interchangeable with lower-cost sodium phenylbutyrate powder.

The most attractive commercial opportunity is a formulation that produces measurable adherence or quality-of-life benefits while retaining the sodium phenylbutyrate mechanism. The least attractive opportunity is a minor excipient substitution that does not materially improve taste, dosing accuracy, sodium burden, or administration convenience.

Key Takeaways

• Pheburane's value is primarily formulation-based, not based on a new active ingredient.
• Taste masking is the central excipient and commercial strategy.
• Ethylcellulose and related coating polymers are likely to be central to formulation differentiation.
• Pheburane's U.S. approval in December 2022 creates a potential orphan-exclusivity horizon through December 2029.
• Formulation patents, if listed or issued, are likely to be more important than compound patents.
• The principal generic risk is a design-around granule or powder product using a different coating system.
• The strongest commercial extensions are pediatric unit-dose packaging, improved administration devices, lower-mass taste masking, and sodium-reduced alternatives.
• Ravicti competes through a different active ingredient and liquid delivery system, while Buphenyl remains the closest same-ingredient comparator.
• Manufacturing complexity, especially high-load coating and dose uniformity, is a meaningful barrier to entry.
• Pheburane's premium depends on documented adherence and administration benefits, not taste masking alone.

FAQs

Can Pheburane granules be administered through feeding tubes?

Administration compatibility depends on the specific tube, vehicle, flushing procedure, and product instructions. Granule retention and coating disruption must be evaluated because tube delivery can change dose recovery and taste exposure.

Could a generic use the same sodium phenylbutyrate but different excipients?

Yes. A generic developer could pursue a different excipient system if it meets FDA requirements and avoids valid formulation claims. A different excipient combination does not, by itself, eliminate bioequivalence or manufacturing obligations.

Is Pheburane protected by a new chemical entity patent?

No. Sodium phenylbutyrate predates Pheburane's approval. The relevant protection is more likely to arise from formulation, manufacturing, method-of-use, orphan-drug, or product-specific regulatory rights.

What excipient is most important for Pheburane's commercial differentiation?

The coating system, particularly the polymer barrier that limits immediate sodium phenylbutyrate release in the mouth, is the most commercially important excipient strategy.

Could a sodium-free phenylbutyrate product replace Pheburane?

A sodium-free product could address a limitation of sodium phenylbutyrate, but it would likely require a distinct development and regulatory pathway. It would compete through reduced sodium exposure rather than through an incremental excipient change.

References

1. U.S. Food and Drug Administration. (2022). Pheburane: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2022). Drugs@FDA: Pheburane, NDA 214992. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. European Medicines Agency. (2023). Pheburane: Summary of product characteristics. EMA. https://www.ema.europa.eu/

4. Medunik Canada. (2023). Pheburane product monograph. Medunik Canada.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

6. U.S. Food and Drug Administration. (2024). Ravicti: Prescribing information. FDA.